Table 4.
Susceptibilities of Pseudomonas aeruginosa Isolates in Each 4-Year Period for 4 Regions
| Susceptibility % by Time Perioda | ||||||
|---|---|---|---|---|---|---|
| Region Antimicrobial Agent | 1997–2000 | 2001–2004 | 2005–2008 | 2009–2012 | 2013–2016 | Overall |
| All regions (n) | (9512) | (7928) | (7170) | (10 951) | (16 461) | (52 022) |
| Amikacin | 89.3 | 88.4 | 88.9 | 90.3 | 93.1 | 90.5 |
| Cefepime | 79 | 77.0 | 77.8 | 76.5 | 83.1 | 79.3 |
| Ceftazidime | 77.2 | 76.6 | 74.9 | 75.0 | 80.8 | 77.5 |
| Ciprofloxacin | 74 | 69.9 | 70.8 | 71.7 | 75.7 | 73 |
| Colistinb | N/A | N/A | 99.4 | 99.2 | 99.5 | 99.4 |
| Meropenem | 80.7 | 75.1 | 73.4 | 72.7 | 77.4 | 76.1 |
| Piperacillin-tazobactam | 73.4 | 70.6 | 70.7 | 70.1 | 77.4 | 73.2 |
| Tobramycin | 83.4 | 80.4 | 81.6 | 84.2 | 88.8 | 84.6 |
| North America (n) | (4380) | (2763) | (2129) | (4351) | (8847) | (22 470) |
| Amikacin | 95.4 | 96.7 | 96.1 | 97.1 | 96.7 | 96.4 |
| Cefepime | 83.1 | 85.5 | 83.7 | 83.4 | 86.1 | 84.7 |
| Ceftazidime | 80.7 | 85.6 | 81.4 | 82.7 | 85.1 | 83.5 |
| Ciprofloxacin | 76.8 | 74.5 | 75.7 | 76.3 | 78.0 | 76.8 |
| Colistin | N/A | N/A | 99.9 | 99.1 | 99.6 | 99.5 |
| Meropenem | 85.2 | 83.2 | 79 | 80.3 | 81.8 | 82.1 |
| Piperacillin-tazobactam | 78.5 | 79.7 | 77.1 | 77.5 | 81.6 | 79.5 |
| Tobramycin | 91.9 | 92.7 | 90.5 | 92.4 | 93.0 | 92.4 |
| Europe (n) | (2380) | (2947) | (2712) | (3762) | (5620) | (17 421) |
| Amikacin | 85.7 | 87.9 | 90.5 | 87.2 | 87.8 | 87.8 |
| Cefepime | 77.2 | 75.2 | 79.6 | 73.4 | 78.2 | 76.7 |
| Ceftazidime | 77.1 | 74.8 | 76.1 | 70.1 | 74.4 | 74.2 |
| Ciprofloxacin | 71.3 | 69.3 | 72.2 | 68.3 | 70.9 | 70.3 |
| Colistin | N/A | N/A | 99.6 | 99.4 | 99.5 | 99.5 |
| Meropenem | 76.5 | 73.3 | 74.2 | 68.9 | 70.6 | 72.1 |
| Piperacillin-tazobactam | 71.9 | 68.6 | 73.4 | 66.2 | 70.8 | 70.0 |
| Tobramycin | 75.1 | 75.9 | 81.3 | 78.5 | 82.3 | 79.3 |
| Asia-Pacific (n) | (1243) | (792) | (811) | (1327) | (1236) | (5409) |
| Amikacin | 96.5 | 94.4 | 91.6 | 94.2 | 95.0 | 94.5 |
| Cefepime | 84.8 | 82.2 | 77.4 | 79.0 | 86.8 | 82.3 |
| Ceftazidime | 81.2 | 81.4 | 75.2 | 77.5 | 81.9 | 79.6 |
| Ciprofloxacin | 85.8 | 82.1 | 77.3 | 80.8 | 83.6 | 82.2 |
| Colistin | N/A | N/A | 97.2 | 98.6 | 99.1 | 98.5 |
| Meropenem | 84.7 | 80.8 | 79.4 | 77.1 | 82.8 | 81.1 |
| Piperacillin-tazobactam | 77.7 | 74.2 | 69.4 | 71.8 | 80.2 | 75.1 |
| Tobramycin | 92.0 | 88.5 | 87.8 | 91.8 | 93.7 | 91.2 |
| Latin America (n) | (1509) | (1426) | (1518) | (1511) | (758) | (6722) |
| Amikacin | 71.4 | 70.2 | 74.8 | 74.9 | 86.8 | 74.4 |
| Cefepime | 65.1 | 61.4 | 66.5 | 62.3 | 77.2 | 65.4 |
| Ceftazidime | 64.2 | 60.1 | 63.2 | 62.8 | 74.6 | 64.0 |
| Ciprofloxacin | 60.5 | 55.7 | 57.9 | 58.8 | 71.1 | 59.7 |
| Colistin | N/A | N/A | 99.8 | 99.4 | 99.1 | 99.5 |
| Meropenem | 70.8 | 59.7 | 61.2 | 56.2 | 67.7 | 62.7 |
| Piperacillin-tazobactam | 57.3 | 54.7 | 57.7 | 57.4 | 73.1 | 58.7 |
| Tobramycin | 64.5 | 61.2 | 66.2 | 68 | 80.6 | 66.8 |
Abbreviations: CLSI, Clinical and Laboratory Standards Institute; N/A, not available.
aSusceptible based on criteria as published by CLSI 2018.
bAgent added in 2006.